rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2017-13-1-69-79rpcardio-1418Research ArticleINNOVATIVE CARDIOLOGYИННОВАЦИОННАЯ КАРДИОЛОГИЯFROM PERSONALIZED TO PRECISION MEDICINEОТ ПЕРСОНАЛИЗИРОВАННОЙ К ТОЧНОЙ МЕДИЦИНЕРаскинаК. В.RaskinaK. V.

Кира Вадимовна Раскина – аспирант кафедры эндокринологии.

119991, Москва, ул. Трубецкая, 8 стр. 2

Kira V. Raskina – MD, PhD Student, Chair of Endocrinology.

Trubetskaya ul. 8, Moscow, 119991

МартыноваЕ. Ю.MartynovaE. Y.

Евгения Юрьевна Мартынова – аспирант кафедры эндокринологии.

119991, Москва, ул. Трубецкая, 8 стр. 2

Eugenia Yu. Martynova – MD, PhD Student, Chair of Endocrinology.

Trubetskaya ul. 8, Moscow, 119991

ПерфильевА. В.PerfilyevA. V.

Андрей Валентинович Перфильев – генеральный директор МЦ «Атлас»; медицинский директор, биомедицинский холдинг «Атлас».

121170, Москва, Кутузовский просп., 34, стр. 14

Andrey V. Perfilyev – MD, Chief Executive Officer.

Kutuzovsky prosp. 34-14, Moscow, 121170 Russia

СычевД. А.SychevD. A.

Дмитрий Алексеевич Сычев – доктор медицинских наук, профессор, член-корр. РАН, зав. кафедрой клинической фармакологии и терапии.

125284, Москва, ул. Поликарпова, 12/13

Dmitry A. Sychev - MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of Chair of Clinical Pharmacology and Therapeutics.

Polikarpova ul. 12/13, Moscow, 125284

ШуевГ. Н.ShuevG. N.

Григорий Николаевич Шуев – аспирант кафедры клинической фармакологии и терапии.

125284, Москва, ул. Поликарпова, 12/13

Grigoriy N. Shuev - MD, PhD Student, Chair of Clinical Pharmacology and Therapeutics.

Polikarpova ul. 12/13, Moscow, 125284

ФатхутдиновИ. Р.FatkhutdinovI. R.

Илдус Рифкатович Фатхутдинов – главный врач.

121170, Москва, Кутузовский просп., 34, стр. 14

Ildus R. Fatkhutdinov - MD, Chief Medical Officer.

Kutuzovsky prosp. 34-14, Moscow, 121170 Russia

МусиенкоС. В.MusienkoS. V.

Сергей Владимирович Мусиенко – генеральный директор.

121069, Москва, ул. Малая Никитская, 31

Sergey V. Musienko - Chief Executive Officer.

Malaya Nikitskaya ul. 31,  Moscow,121069

НикогосовД. А.NikogosovD. A.

Дмитрий Аркадьевич Никогосов – руководитель отдела аналитики.

121069, Москва, ул. Малая Никитская, 31

Dmitry A. Nikogosov MD, Head of Analytics Department.

Malaya Nikitskaya ul. 31,  Moscow,121069

ЖегулинаИ. О.ZhegulinaI. O.

Ирина Олеговна Жегулина – врач-генетик.

121170, Москва, Кутузовский просп., 34, стр. 14

Irina O. Zhegulina MD, Geneticist.

Kutuzovsky prosp. 34-14, Moscow, 121170 Russia

БавыкинаЛ. Г.BavykinaL. G.

Лариса Геннадьевна Бавыкина – врач эндокринолог-генетик.

121170, Москва, Кутузовский просп., 34, стр. 14

Larisa G. Bavykina MD, Endocrinologist, Geneticist.

Kutuzovsky prosp. 34-14, Moscow, 121170 Russia

ПотешкинЮ. Е.PoteshkinY. E.

Юрий Евгеньевич Потешкин – кандидат медицинских наук,  зав. научно-клиническим центром эндокринологии, медицинский центр «Атлас»; доцент кафедры эндокринологии лечебного факультета, РНИМУ им. Н.И. Пирогова.

121170, Москва, Кутузовский просп., 34, стр. 14; 117997, Москва, ул. Островитянова, 1

Kutuzovsky prosp. 34-14, Moscow, 121170; Ostrovitianova ul. 1, Moscow, 117997

yep@actmed.ruПервый Московский государственный медицинский университет имени И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical University.Russian FederationПервый Московский государственный медицинский университет имени И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian FederationМедицинский центр «Атлас»РоссияMedical Center "Atlas"Russian FederationРоссийская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Postgraduate EducationRussian FederationБиомедицинский холдинг «Атлас»РоссияBiomedical Group "Atlas"Russian FederationМедицинский центр «Атлас»; Российский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияMedical Center "Atlas";Pirogov Russian National Research Medical UniversityRussian Federation2017030320171316979Copyright © Raskina K.V., Martynova E.Y., Perfilyev A.V., Sychev D.A., Shuev G.N., Fatkhutdinov I.R., Musienko S.V., Nikogosov D.A., Zhegulina I.O., Bavykina L.G., Poteshkin Y.E., 20172017Раскина К.В., Мартынова Е.Ю., Перфильев А.В., Сычев Д.А., Шуев Г.Н., Фатхутдинов И.Р., Мусиенко С.В., Никогосов Д.А., Жегулина И.О., Бавыкина Л.Г., Потешкин Ю.Е.Raskina K.V., Martynova E.Y., Perfilyev A.V., Sychev D.A., Shuev G.N., Fatkhutdinov I.R., Musienko S.V., Nikogosov D.A., Zhegulina I.O., Bavykina L.G., Poteshkin Y.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1418

The need to maintain a high quality of life against a backdrop of its inevitably increasing duration is one of the main problems of modern health care. The concept of "right drug to the right patient at the right time", which at first was bearing the name "personalized", is currently unanimously approved by international scientific community as "precision medicine". Precision medicine takes all the individual characteristics into account: genes diversity, environment, lifestyles, and even bacterial microflora and also involves the use of the latest technological developments, which serves to ensure that each patient gets assistance fitting his state best. In the United States, Canada and France national precision medicine programs have already been submitted and implemented. The aim of this review is to describe the dynamic integration of precision medicine methods into routine medical practice and life of modern society. The new paradigm prospects description are complemented by figures, proving the already achieved success in the application of precise methods for example, the targeted therapy of cancer. All in all, the presence of real-life examples, proving the regularity of transition to a new paradigm, and a wide range  of technical and diagnostic capabilities available and constantly evolving make the all-round transition to precision medicine almost inevitable.

Необходимость поддержания высокого  качества жизни при неотвратимо растущей  ее продолжительности является одной  из главных проблем современного здравоохранения. Концепция «правильного препарата для правильного пациента в правильное время», вначале носившая название «персонализированной», в настоящее время единогласно утверждена мировым научным сообществом под названием «точная медицина». Точная медицина принимает во внимание индивидуальные особенности: разнообразие генов,  условий  окружающей среды, образов жизни и даже бактериальной микрофлоры, а также предполагает применение новейших технических достижений, что призвано обеспечить каждого  пациента помощью, которая будет лучше всего соответствовать именно его состоянию. В США, Канаде и Франции уже представлены и реализуются национальные программы по точной медицине.

Целью этого обзора является  описание динамической интеграции методов точной медицины в рутинную врачебную практику и жизнь современного общества. Описание перспектив новой парадигмы дополнено иллюстрациями, свидетельствующими об уже достигнутых успехах в применении точных методов – к примеру, таргетной терапии  раковых  заболеваний.

Так, наличие реальных примеров, доказывающих планомерность перехода к новой парадигме, и широкий спектр технических и диагностических возможностей – доступных и постоянно развивающихся – в сумме делают повсеместный переход к точной медицине практически неизбежным.

точная медицинаперсонализированная медицинапрецизионная медицинагеномные исследованияprecision medicinepersonalized medicineprecision medicinegenomic researchReferencesEmmert-Streib F. Personalized medicine: Has it started yet? A reconstruction of the early history. Front Genet. 2013;3:1-4.Emmert-Streib F. Personalized medicine: Has it started yet? A reconstruction of the early history. Front Genet. 2013;3:1-4.Genetic Science Learning Center. What is Precision Medicine? Available at: http://learn.genetics.utah.edu/content/precision/intro/. Checked by Feb 10, 2017.Genetic Science Learning Center. What is Precision Medicine? Available at: http://learn.genetics.utah.edu/content/precision/intro/. Checked by Feb 10, 2017.The Precision Medicine Initiative. The White House, Statements & Releases (2016). Available at: https://www.whitehouse.gov/precision-medicine. Checked by Feb 10, 2017.The Precision Medicine Initiative. The White House, Statements & Releases (2016). Available at: https://www.whitehouse.gov/precision-medicine. Checked by Feb 10, 2017.Singer D.R.J., Zair Z.M. Clinical Perspectives on Targeting Therapies for Personalized Medicine. Adv Protein Chem Struct Biol. 2016;102:79-114.Singer D.R.J., Zair Z.M. Clinical Perspectives on Targeting Therapies for Personalized Medicine. Adv Protein Chem Struct Biol. 2016;102:79-114.Juengst E., McGowan M.L., Fishman J.R., Settersten R. From “Personalized” to “Precision” Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine. Hastings Cent Rep. 2016;46(5):21-33.Juengst E., McGowan M.L., Fishman J.R., Settersten R. From “Personalized” to “Precision” Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine. Hastings Cent Rep. 2016;46(5):21-33.Vinks A. Therapeutic Optimization as Part of the Precision Medicine Paradigm. Clin Pharmacol Ther. 2016;99(4):340-2.Vinks A. Therapeutic Optimization as Part of the Precision Medicine Paradigm. Clin Pharmacol Ther. 2016;99(4):340-2.Bonham V.L., Callier S.L., Royal C.D. Will Precision Medicine Move Us beyond Race? N Engl J Med. 2016;374(21):2003-5.Bonham V.L., Callier S.L., Royal C.D. Will Precision Medicine Move Us beyond Race? N Engl J Med. 2016;374(21):2003-5.Interlandi J. The Paradox of Precision Medicine. Sci Am. 2016;314(4):24-5.Interlandi J. The Paradox of Precision Medicine. Sci Am. 2016;314(4):24-5.Joyner M.J., Paneth N. Seven Questions for Personalized Medicine. JAMA. 2015;55905:2015-6.Joyner M.J., Paneth N. Seven Questions for Personalized Medicine. JAMA. 2015;55905:2015-6.Reardon S. Obama to seek $215 million for precision-medicine plan. Nature. 2015:1-2.Reardon S. Obama to seek $215 million for precision-medicine plan. Nature. 2015:1-2.Merieux F. Presentation of the French Plan for Genomic Medicine 2025 | Newsroom | Inserm. (2016). Available at: http://presse.inserm.fr/en/presentation-of-the-french-plan-for-genomic-medicine-2025/24328/. Checked by Feb 10, 2017.Merieux F. Presentation of the French Plan for Genomic Medicine 2025 | Newsroom | Inserm. (2016). Available at: http://presse.inserm.fr/en/presentation-of-the-french-plan-for-genomic-medicine-2025/24328/. Checked by Feb 10, 2017.France Plans to Invest €670M in Genomics, Personalized Medicine. Genome Web (2016). Available at: https://www.genomeweb.com/clinical-translational/france-plans-invest-670m-genomics-personalized-medicine. Checked by Feb 10, 2017.France Plans to Invest €670M in Genomics, Personalized Medicine. Genome Web (2016). Available at: https://www.genomeweb.com/clinical-translational/france-plans-invest-670m-genomics-personalized-medicine. Checked by Feb 10, 2017.French plans for a genomic healthcare future. Genomics Educ Program (2016). Available at: https://www.genomicseducation.hee.nhs.uk/news/item/266-french-plans-for-a-genomic-healthcare-future. Checked by Feb 10, 2017.French plans for a genomic healthcare future. Genomics Educ Program (2016). Available at: https://www.genomicseducation.hee.nhs.uk/news/item/266-french-plans-for-a-genomic-healthcare-future. Checked by Feb 10, 2017.Cullis P., Huntsman D., Mcmanus B., et al. Personalized Medicine Initiative Canada (2016). Available at: http://personalizedmedicineinitiative.ca/. Checked by Feb 10, 2017.Cullis P., Huntsman D., Mcmanus B., et al. Personalized Medicine Initiative Canada (2016). Available at: http://personalizedmedicineinitiative.ca/. Checked by Feb 10, 2017.Cullis P., Drohan J., Fraser R. Roadmap for Bringing Personalized Medicine to British Columbians Summit Partners. Available at: http://www.pwc.com/ca/en/healthcare/publications/pwc-personalizedmedicine-summit-green-paper-2015-06-en.pdf. Checked by Feb 10, 2017.Cullis P., Drohan J., Fraser R. Roadmap for Bringing Personalized Medicine to British Columbians Summit Partners. Available at: http://www.pwc.com/ca/en/healthcare/publications/pwc-personalizedmedicine-summit-green-paper-2015-06-en.pdf. Checked by Feb 10, 2017.U.S. Food and Drug Administration. Paving the Way for Personalized Medicine Paving the Way for Personalized Medicine. Per Med. 2013:5-11.U.S. Food and Drug Administration. Paving the Way for Personalized Medicine Paving the Way for Personalized Medicine. Per Med. 2013:5-11.Spear B.B., Heath-Chiozzi M., Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-4.Spear B.B., Heath-Chiozzi M., Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-4.Personalized Medicine Coalition. More than 20 percent of the Novel New Drugs Approved by FDA’s Center for Drug Evaluation and Research in 2014 are Personalized Medicines (2014). Available at: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/fda-approvals-personalized-medicine-2014_adjusted.pdf. Checked by Feb 10, 2017.Personalized Medicine Coalition. More than 20 percent of the Novel New Drugs Approved by FDA’s Center for Drug Evaluation and Research in 2014 are Personalized Medicines (2014). Available at: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/fda-approvals-personalized-medicine-2014_adjusted.pdf. Checked by Feb 10, 2017.U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: http://www.fda.gov/Drugs/Scienceresearch/Researchareas/Pharmacogenetics/Ucm083378Htm. 2015:1-14. doi:08/18/2014. Checked by Feb 10, 2017.U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: http://www.fda.gov/Drugs/Scienceresearch/Researchareas/Pharmacogenetics/Ucm083378Htm. 2015:1-14. doi:08/18/2014. Checked by Feb 10, 2017.Druker B.J., Guilhot F., O’Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.Druker B.J., Guilhot F., O’Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.Sychev D.A. Recommendations for the use of pharmacogenetic testing in clinical practice. Kachestvennaya Klinicheskaya Praktika. 2011; 1: 3-10. (In Russ.) [Сычев Д.А. Рекомендации по применению фармакогенетического тестирования в клинической практике. Качественная Клиническая Практика. 2011;1:3-10].Sychev D.A. Recommendations for the use of pharmacogenetic testing in clinical practice. Kachestvennaya Klinicheskaya Praktika. 2011; 1: 3-10. (In Russ.) [Сычев Д.А. Рекомендации по применению фармакогенетического тестирования в клинической практике. Качественная Клиническая Практика. 2011;1:3-10].Personalized Medicine Coalition. U.S. Public Opinion about Personalized Medicine Survey Shows Public Optimism about Personalized Medicine (2013). Available at: http://personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/us_public_opinion_about_personalized_medicine.pdf. Checked by Feb 10, 2017.Personalized Medicine Coalition. U.S. Public Opinion about Personalized Medicine Survey Shows Public Optimism about Personalized Medicine (2013). Available at: http://personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/us_public_opinion_about_personalized_medicine.pdf. Checked by Feb 10, 2017.Personalized medicine by the numbers Prominent examples of personalized medicine drugs, treatments and diagnostics products available (2014). Available at:http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_personalized_medicine_by_the_numbers.pdf. Checked by Feb 10, 2017.Personalized medicine by the numbers Prominent examples of personalized medicine drugs, treatments and diagnostics products available (2014). Available at:http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_personalized_medicine_by_the_numbers.pdf. Checked by Feb 10, 2017.Loria K. The history of medicine will seem blunt and random compared with what’s coming next. Bus Insid. (2015). Available at: http://www.businessinsider.com/what-the-precision-medicine-initiativewill-do-2015-5. Checked by Feb 10, 2017.Loria K. The history of medicine will seem blunt and random compared with what’s coming next. Bus Insid. (2015). Available at: http://www.businessinsider.com/what-the-precision-medicine-initiativewill-do-2015-5. Checked by Feb 10, 2017.

The authors declare that there are no conflicts of interest present.